跳到正文
原文
STAT 主站· Elaine Chen·· 23 天前AI 评分55

礼来称在研药retatrutide在大型糖尿病研究中头对头优于Ozempic

STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study

AI 导读

礼来称其在研药物retatrutide在一项大型糖尿病研究中降低血糖和减轻体重的效果优于诺和诺德的Ozempic。该结果由礼来对外公布,材料未披露具体数据,retatrutide仍属在研药物。同一期简报还提到一项细胞疗法自身免疫试验中出现两例死亡,以及Epic在患者数据方面的主导地位。

正文

Two deaths reported in cell therapy autoimmune trial, Epic’s dominance over patient data, and more biotech news

Scott Olson/Getty Images

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. We’ve got lots of news today to get into.

Lilly’s triple-G drug beats Ozempic in head-to-head study

Eli Lilly said this morning that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

  1. National Biotech Reporter

    Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.

来源:STAT 主站 · statnews.com